Breaking News

Tweet TWEET

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock 
SAN DIEGO, CA -- (Marketwired) -- 12/18/13 --  Adamis Pharmaceuticals
Corporation (NASDAQ: ADMP) today announced the closing of its
previously announced underwritten public offering of 3,720,000 shares
of common stock at a public offering price of $5.95 per share. The
gross proceeds to Adamis from the offering are $22,134,000, before
deducting underwriting discounts and commissions and other estimated
offering expenses payable by Adamis.  
Adamis intends to use approximately $7 million of the net proceeds
from the offering to make the final payment to acquire the assets
relating to the Taper dry powder inhaler technology pursuant to an
agreement that the company entered into earlier this year. An
additional approximately $7.2 million of the net proceeds are also
expected to be used to pay in full all amounts owed under unconverted
convertible promissory notes that were issued in a private placement
financing transaction in June 2013. Remaining net proceeds are
expected to be used to fund efforts to obtain regulatory approval for
and launch the company's Epinephrine PFS syringe product candidate,
fund clinical trials and product development efforts, and for working
capital and general corporate purposes, including payment of
outstanding obligations and indebtedness. 
CRT Capital Group, LLC acted as sole book-running manager for the
offering, and Newport Coast Securities, Inc. acted as co-manager of
the offering. 
A registration statement on Form S-1 relating to the shares of common
stock offered by the company was filed with the Securities and
Exchange Commission and is effective. The final prospectus relating
to the offering has been filed with the SEC and is available on the
SEC's web site at http://www.sec.gov. Copies of the final prospectus
may be obtained from the SEC's web site or from CRT Capital Group
LLC, 262 Harbor Drive, Stamford, CT 06902. 
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale is not permitted. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is 
a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. The company's
current specialty pharmaceutical product candidates include the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The company's vaccine product candidates and cancer drug
product candidates under research and development include TeloB-VAX,
a cell-based therapeutic cancer vaccine and three drugs, APC-100,
APC-200, and APC-300, for the treatment of prostate cancer. 
Adamis Contacts 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.